| Ytd | 10.25% | |
| 1y | 124.75% |
| Open | 13.50 | Prev Close | 13.31 | Low | 13.10 | High | 14.25 | Mkt Cap | 356.50M |
| Vol | 2.04M | Avg Vol | 1.15M | EPS | -1.40 | P/E | -9.60 | Forward P/E | -1.06 |
| Beta | 2.15 | Short Ratio | 1.46 | Inst. Own | 47.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 13.61 | 200-d Avg | 12.29 | 1yr Est | 16.30 |
TENX News
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL,
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the s
Tenax Therapeutics, Inc. is downgraded from Buy to Hold ahead of a major August 2026 phase 3 data re
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax”
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercia
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHA
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving av
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) crossed above its 200-day moving
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter
Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free R
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tena
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax
Tenax Therapeutics is a speculative BUY, driven by the commercial potential of levosimendan for PH-H
Tenax Therapeutics (TENX) initiated with a Buy rating and a $25 price target, implying 127% upside b
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LE
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United The
On Wednesday, 116 companies set new 52-week lows.
On Tuesday, 400 companies set new 52-week lows.